This continuing feature updates readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number 1 killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, if pharmacists stay current with developments in drug therapy, they can have a significant impact on prevention and treatment.
Get full access to this article
View all access options for this article.
References
1.
ConwayE., MuscoS., KoweyP.R.New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?Am J Cardiol.2008; 102(6A): 12H–19H.
2.
FeinbergW.M., BlackshearJ.L., LaupacisA., KronmalR., HartR.G.Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med.1995; 155(5): 469–473.
3.
GoA.S., HylekE.M., PhillipsK.A.Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA.2001; 285(18): 2370–2375.
4.
SingerD.E., AlbersG.W., DalenJ.E.; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest.2008; 133(6)(suppl): 546S–592S.
5.
FusterV., RydénL.E., CannomD.S.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation); developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published correction appears in Circulation. 2007;116(6): e138]. Circulation.2006; 114(7): e257–e354.
6.
HohnloserS.H., KuckK.H., LillenthalJ.Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet.2000; 356(9244): 1789–1794.
7.
WyseD.G., WaldoA.L., DiMarcoJ.P.; The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med.2002; 347(23): 1825–1833.
8.
Van GelderI.C., HagensV.E., BoskerH.A.; The Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med.2002; 347(23): 1834–1840.
9.
CarlssonJ., MiketicS., WindelerJ.Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol.2003; 41(10): 1690–1696.
10.
MasonJ.W.Amiodarone. N Engl J Med.1987; 316(8): 455–466.
11.
ChowM.S.Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother.1996; 30(6): 637–643.
12.
VassalloP., TrohmanR.G.Prescribing amiodarone: an evidence-based review of clinical indications. JAMA.2007; 298(11): 1312–1322.
13.
LaughlinJ.C., KoweyP.R.Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol.2008; 19(11): 1220–1226.
14.
SinghB.N., ConnollyS.J., CrijnsH.J.; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med.2007; 357(10): 987–999.
15.
KøberL., Torp-PedersenC., McMurrayJ.J.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med.2008; 358(25): 2678–2687.
16.
HohnloserS.H., CrijnsH.J., van EickelsM.; ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med.2009; 360(7): 668–678.
